Identification of AMP N1-oxide in royal jelly as a component neurotrophic toward cultured rat pheochromocytoma PC12 cells

Bioscience, Biotechnology and Biochemistry

Volumn 70, Issue 4, 2006, Pages 897-906

  Hattori, Noriko ^a,b   Nomoto, Hiroshi ^a   Mishima, Satoshi ^b   Inagaki, Shinsuke ^a   Goto, Masashi ^a   Sako, Magoichi ^a   Furukawa, Shoei ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b Api Company Ltd   (Japan)

Author keywords

Adenosine monophosphate (AMP) N1 oxide; Adenosine receptor; Neuronal differentiation; PC12 cells; Royal jelly (RJ)

Indexed keywords

CELLS; CONCENTRATION (PROCESS); NEUROLOGY; PROTEINS;

ADENOSINE MONOPHOSPHATE (AMP) N1-OXIDE; ADENOSINE RECEPTOR; NEURONAL DIFFERENTIATION; PC12 CELLS; ROYAL JELLY (RJ);

NITROGEN OXIDES;

ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; AMP N1 OXIDE; AMP N1-OXIDE; DRUG DERIVATIVE; FATTY ACID; OXIDE; ROYAL JELLY;

ANIMAL; ARTICLE; CELL MOTION; CELL PROLIFERATION; CELL SHAPE; CELL STRAIN; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; ELECTROSPRAY MASS SPECTROMETRY; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; METABOLISM; NERVE CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT;

ADENOSINE MONOPHOSPHATE; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELL SHAPE; CHROMATOGRAPHY, ION EXCHANGE; FATTY ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; NEURONS; OXIDES; PC12 CELLS; RATS; RECEPTORS, PURINERGIC P1; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 33646127159     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.70.897     Document Type: Article

References (42)

1. Angelucci, F., Mathe, A. A., and Aloe, L., Neurotrophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Prog. Brain Res., 146, 151-165 (2004).
2. Duman, R. S., Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol. Med., 5, 11-25 (2004).
3. Tuszynski, M. H., and Blesch, A., Nerve growth factor: from animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer's disease. Prog. Brain Res., 146, 441-449 (2004).
4. Kamakura, M., Mitani, N., Fukuda, T., and Fukushima, M., Antifatigue effect of fresh royal jelly in mice. J. Nutr. Sci. Vitaminol. (Tokyo), 47, 394-401 (2001).
5. Fujii, A., Kobayashi, S., Kuboyama, N., Furukawa, Y., Kaneko, Y., Ishihama, S., Yamamoto, H., and Tamura, T., Augmentation of wound healing by royal jelly (RJ) in streptozotocin-diabetic rats. Jpn. J. Pharmacol., 53, 331-337 (1990).
6. Sver, L., Orsolic, N., Tadic, Z., Njari, B., Valpotic, I., and Basic, I., A royal jelly as a new potential immunomodulator in rats and mice. Comp. Immunol. Microbiol. Infect. Dis., 19, 31-38 (1996).
7. Oka, H., Emori, Y., Kobayashi, N., Hayashi, Y., and Nomoto, K., Suppression of allergic reactions by royal jelly in association with the restoration of macrophage function and the improvement of Th1/Th2 cell responses. Int. Immunopharmacol., 1, 521-532 (2001).
8. Taniguchi, Y., Kohno, K., Inoue, S., Koya-Miyata, S., Okamoto, I., Arai, N., Iwaki, K., Ikeda, M., and Kurimoto, M., Oral administration of royal jelly inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. Int. Immunopharmacol., 3, 1313-1324 (2003).
9. Tokunaga, K. H., Yoshida, C., Suzuki, K. M., Maruyama, H., Futamura, Y., Araki, Y., and Mishima, S., Antihypertensive effect of peptides from royal jelly in spontaneously hypertensive rats. Biol. Pharm. Bull., 27, 189-192 (2004).
10. Greene, L. A., and Tischler, A. S., Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA, 73, 2424-2428 (1976).
11. Chao, M. V., The p75 neurotrophin receptor. J. Neurobiol., 25, 1373-1385 (1994).
12. Barbacid, M., The Trk family of neurotrophin receptors. J. Neurobiol., 25, 1386-1403 (1994).
13. Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., and Parada, L. F., The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science, 252, 554-558 (1991).
14. Lin, W. H., Higgins, D., Pacheco, M., Aletta, J., Perini, S., Marcucci, K. A., and Roth, J. A., Manganese induces spreading and process outgrowth in rat pheochromocytoma (PC12) cells. J. Neurosci. Res., 34, 546-561 (1993).
15. Tsai, S. S., Sun, A. Y., Kim, H. D., and Sun, G. Y., Manganese exposure to PC-12 cells alters triacylglycerol metabolism and promotes neurite outgrowth. Life Sci., 52, 1567-1575 (1993).
16. Gunning, P. W., Letourneau, P. C., Landreth, G. E., and Shooter, E. M., The action of nerve growth factor and dibutyryl adenosine cyclic 3′:5′-monophosphate on rat pheochromocytoma reveals distinct stages in the mechanisms underlying neurite outgrowth. J. Neurosci., 1, 1085-1095 (1981).
17. Rogers, M. V., Buensuceso, C., Montague, F., and Mahadevan, L., Vanadate stimulates differentiation and neurite outgrowth in rat pheochromocytoma PC12 cells and neurite extension in human neuroblastoma SH-SY5Y cells. Neuroscience, 60, 479-494 (1994).
18. Campbell, X. Z., and Neet, K. E., Hierarchical analysis of the nerve growth factor-dependent and nerve growth factor-independent differentiation signaling pathways in PC12 cells with protein kinase inhibitors. J. Neurosci. Res., 42, 207-219 (1995).
19. Parker, E. M., Monopoli, A., Ongini, E., Lozza, G., and Babij, C. M., Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression. Neuropharmacology, 39, 1913-1919 (2000).
20. Nomoto, H., Tomotoshi, K., Ito, H., and Furukawa, S., Balance of two secretion pathways of nerve growth factor in PC12 cells changes during the progression of their differentiation, with a decrease in constitutive secretion in more differentiated cells. J. Neurosci. Res., 59, 632-642 (2000).
21. Furukawa, S., Kamo, I., Furukawa, Y., Akazawa, S., Satoyoshi, E., Itoh, K., and Hayashi, K., A highly sensitive enzyme immunoassay for mouse beta nerve growth factor. J. Neurochem., 40, 734-744 (1983).
22. McCormick, D. B., Syntheses, characterizations, and biochemical reactivities of 1-N-oxides of 5′-adenylic and 5′-inosinic acids. Biochemistry, 5, 746-751 (1966).
23. Lipps, B. V., Detection of nerve growth factor (NGF) in venoms from diverse source: isolation and characterization of NGF from the venom of honey bee (Apis melifera). J. Nat. Toxins, 9, 13-19 (2000).
24. Lipps, B. V., Antigenic cross-reactivity of nerve growth factors from diverse source: activity versus toxicity of NGF. J. Nat. Toxins, 11, 57-62 (2002).
25. Barker, S. A., Foster, A. B., Lamb, D. C., and Hodgson, N., Identification of 10-hydroxy-delta 2-decenoic acid in royal jelly. Nature, 183, 996-997 (1959).
26. Blum, M. S., Novak, A. F., and Taber, S., 3rd., 10-Hydroxy-delta 2-decenoic acid, an antibiotic found in royal jelly. Science, 130, 452-453 (1959).
27. Townsend, G. F., Morgan, J. F., and Hazlett, B., Activity of 10-hydroxydecenoic acid from royal jelly against experimental leukaemia and ascitic tumours. Nature, 183, 1270-1271 (1959).
28. Rudkin, B. B., Lazarovici, P., Levi, B. Z., Abe, Y., Fujita, K., and Guro., G., Cell cycle-specific action of nerve growth factor in PC12 cells: differentiation without proliferation. EMBO J., 8, 3319-3325 (1989).
29. Fredholm, B. B., Ijzerman, A. P., Jacobson, K. A., Klotz, K. N., and Linden, J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 53, 527-552 (2001).
30. 2A adenosine receptor in four PC12 cell clones. Naunyn Schmiedebergs Arch. Pharmacol., 359, 28-32 (1999).
31. Brown, D. M., and Osborne, M. R., The reaction of adenosine with hydroxylamine. Biochim. Biophys. Acta, 247, 514-518 (1971).
32. Mantsch, H. H., and Barzu, O., Anomalous base-stacking of the N1-oxide of AMP. Z. Naturforsch. C, 32, 901-904 (1977).
33. Brown, G. B., Clarke, D. A., Biesele, J. J., Kaplan, L., and Stevens, M. A., Purine N-oxides. III. Some biological activities of adenine 1-N-oxide derivatives. J. Biol. Chem., 233, 1509-1512 (1958).
34. Montgomery, J. A., Approaches to antiviral chemotherapy. Antiviral Res., 12, 113-131 (1989).
35. Baker, R. O., Bray, M., and Huggins, J. W., Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res., 57, 13-23 (2003).
36. Kane, E. M., and Shuman, S., Adenosine N1-oxide inhibits vaccinia virus replication by blocking translation of viral early mRNAs. J. Virol., 69, 6352-6358 (1995).
37. Kwong, C. D., Krauth, C. A., Shortnacy-Fowler, A. T., Arnett, G., Hollingshead, M. G., Shannon, W. M., Montgomery, J. A., and Secrist, J. A., 3rd., Synthesis and antiviral evaluation of analogs of adenosine-N1-oxide and 1-(Benzyloxy)adenosine. Nucleosides Nucleotides, 17, 1409-1443 (1998).
38. Charles, M. P., Adamski, D., Kholler, B., Pelletier, L., Berger, F., and Wion, D., Induction of neurite outgrowth in PC12 cells by the bacterial nucleoside N6-methyl-deoxyadenosine is mediated through adenosine A2a receptors and via cAMP and MAPK signaling pathways. Biochem. Biophys. Res. Commun., 304, 795-800 (2003).
39. 2A adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade. J. Biol. Chem., 277, 33930-33942 (2002).
40. Lee, F. S., and Chao, M. V., Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA, 98, 3555-3560 (2001).
41. Arslan, G., and Fredholm, B. B., Stimulatory and inhibitory effects of adenosine A (2A) receptors on nerve growth factor-induced phosphorylation of extracellular regulated kinases 1/2 in PC12 cells. Neurosci. Lett., 292, 183-186 (2000).
42. Daval, J. L., Nehlig, A., and Nicolas, F., Physiological and pharmacological properties of adenosine: therapeutic implications. Life Sci., 49, 1435-1453 (1991).